Propha-Masteron 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Usage

1. Confirm vial integrity: inspect the Propha-Masteron vial for particulate matter, cloudiness, or compromised seal — a clear, oil-based solution with an intact aluminium crimp cap indicates a properly sealed product.
2. Wipe the rubber stopper with a 70% isopropyl alcohol swab and allow it to dry completely before each puncture to maintain sterility across the vial's multi-dose use.
3. Draw with a larger-gauge drawing needle (18–21g) to aspirate the oil-based solution efficiently, then swap to a 25–27g injection needle to minimise tissue trauma at the injection site.
4. Select an intramuscular injection site — glute, quad, or deltoid — and ensure the needle length is sufficient to reach muscle depth (typically 1 inch for most users); the intramuscular route is what delivers the full bioavailability advantage over oral administration.
5. Administer on your established every-other-day schedule to maintain stable Drostanolone plasma concentrations consistent with the propionate ester's release kinetics; document injection sites and rotate systematically to prevent localised tissue irritation.
6. Store the opened vial at room temperature (15–25°C), away from UV light; do not freeze or refrigerate, as cooling thickens the oil vehicle and impedes accurate drawing — particularly important at the 100mg/ml concentration where small volume errors have a proportionally larger impact on dose accuracy.

Warnings

Frequently asked questions

Why does injectable Drostanolone Propionate have higher bioavailability than oral anabolic compounds?

Injectable Drostanolone Propionate achieves near-complete systemic bioavailability because intramuscular administration bypasses the liver's first-pass metabolic processing entirely. Oral compounds must pass through the gastrointestinal tract and liver before reaching systemic blood, where enzymatic breakdown can destroy a substantial fraction of the active molecule. Because Drostanolone lacks a 17-alpha-alkyl group, the oral route is not a viable delivery option for this compound at all.

What exactly is first-pass metabolism and how does it affect androgenic compounds taken by mouth?

First-pass metabolism refers to the hepatic and intestinal enzymatic processing that occurs when a swallowed drug enters the portal circulation before reaching systemic blood. For androgenic steroids without liver-protective modifications, this process can degrade the majority of the active compound before it reaches target tissues. Injectable formulations like Propha-Masteron sidestep this entirely — the drug enters venous return from the muscle and travels to the heart and systemic circulation without prior hepatic exposure.

How does the absorption profile of an intramuscular oil depot differ from that of an oral anabolic tablet?

An intramuscular oil depot releases the compound at a rate governed primarily by ester lipophilicity and depot surface area — a relatively controlled and predictable process. Oral tablet absorption depends on gastric pH, intestinal motility, and enterocyte uptake efficiency, all of which vary between individuals and even between doses in the same individual. The intramuscular route therefore produces more consistent plasma concentration profiles, which is particularly relevant for short-ester compounds like Drostanolone Propionate where timing precision matters.

How do you correctly dose Propha-Masteron at 100mg/ml using an insulin syringe for smaller volumes?

At 100mg/ml, Propha-Masteron allows straightforward volume arithmetic: a 0.5ml draw equals 50mg, and a 1ml draw equals 100mg, both well within the capacity of a 1ml insulin-gauge syringe. Using a 25–27 gauge, 1-inch needle minimises injection discomfort while still reaching intramuscular depth in most injection sites. Always draw from the vial with a separate drawing needle and swap to the injection needle before administering to preserve tip integrity.

How should the Propha-Masteron 10ml vial be stored after first opening?

After the rubber stopper is first punctured, Propha-Masteron should be stored at room temperature (15–25°C), away from direct light and heat sources — refrigeration is not necessary and may cause the oil to thicken, making drawing difficult. The multi-dose vial is designed for repeated puncture, but the stopper should be wiped with an alcohol swab before each draw. Once opened, the vial should be used within the timeframe indicated on the label, typically within 28 days for multi-dose injectables. (2) angle_used

Manufacturer

Beligas Pharmaceuticals' product portfolio for its Propha line — short-ester injectable formulations requiring the tightest manufacturing tolerances — represents the clearest expression of the brand's commitment to ester-specific quality engineering. Within this portfolio, Propha-Masteron occupies a distinct category: a non-aromatising cutting agent where concentration precision and sterility are non-negotiable, because the users relying on it during pre-contest phases cannot afford dosing inconsistencies or injection-site reactions at a critical preparation stage. The Propha series as a whole — spanning multiple short-ester active ingredients — is manufactured under a single unified GMP framework, with each individual SKU validated against its own product-specific specification sheet rather than a generic injectable template. For Drostanolone Propionate at 100mg/ml specifically, Beligas applies HPLC potency confirmation to verify that the stated concentration is met within pharmacopoeial tolerance on every released lot. LAL (Limulus Amebocyte Lysate) endotoxin testing is performed at the finished-product stage, not approximated from raw material documentation alone. This portfolio-level discipline — consistent method, product-specific specification — is what positions Beligas's Propha range as a technically coherent product line rather than a collection of reformulated generics.